Although the Woven EndoBridge (WEB) device is increasingly used for the treatment of wide-neck intracranial aneurysms, including in the acute rupture setting, comparative evidence assessing the impact of rupture status remains limited. This study compared angiographic, safety, and clinical outcomes between ruptured and unruptured intracranial aneurysms treated with WEB. We conducted a retrospective analysis of prospectively collected data from the multicenter cohort registry WorldWideWEB, including consecutive adult patients with intracranial aneurysms treated with the WEB. Patients were stratified into groups of ruptured and unruptured aneurysms. Propensity score matching was used to balance baseline characteristics between both groups. Retreatment rate was the primary outcome. Secondary outcomes included mRS, safety events (thromboembolic complications) and angiographic outcomes (periprocedurally and last follow-up). Among 1,220 patients, 342 (28.0
Middle meningeal artery embolization (MMAE) has emerged as a treatment for chronic subdural hematoma (cSDH), but comprehensive real-world safety data remain limited. We performed a multicenter retrospective analysis of 1781 consecutive patients undergoing MMAE for cSDH (2019–2025). The primary outcome was any procedure-related complication within 30 days. Inverse probability of treatment weighting (IPTW) assessed the association between technical success and complications, adjusting for demographic, clinical, and procedural confounders. Mean age was 72.8 ± 12.4 years; 68.1
We present data from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension (LTE) study evaluating repigmentation outcomes with continued 1.5% ruxolitinib cream treatment in patients who did not achieve near-complete facial repigmentation in TRuE-V1/TRuE-V2. Among patients in the TRuE-V1/TRuE-V2 trials who applied ruxolitinib cream from day 1, approximately 66% achieved F-VASI 75 (indicative of treatment success) at week 104, increasing from nearly 31% at week 52 (TRuE-V LTE baseline); similar repigmentation improvements were reported in patients who switched from vehicle to ruxolitinib cream after TRuE-V1/TRuE-V2 at week 24, albeit with lower overall response rates due to the shorter duration of ruxolitinib cream application. These findings indicate that continued ruxolitinib cream treatment allows further repigmentation in many patients.
Middle meningeal artery embolization (MMAE) plus surgical evacuation is increasingly used for chronic subdural hematoma (cSDH), but predictors of length of stay (LOS) and outcomes associated with early discharge remain unclear. We performed a multicenter MESH Registry study (2019–2024) of patients undergoing MMAE and surgical evacuation for symptomatic cSDH. Short-stay discharge was defined as LOS ≤4 days. Predictors were identified using multivariable logistic regression. The 90-day composite adverse event was defined as cSDH recurrence requiring intervention, reintervention (repeat MMAE or surgical evacuation), or 30-day all-cause readmission. Safety was assessed using adjusted logistic regression, generalized estimating equations (GEE), inverse probability of treatment weighting (IPTW), and multiple imputation by chained equations (MICE). Among 647 patients (mean age 72.6 years; 74.0
OBJECTIVES:Posttraumatic stress disorder (PTSD) is a psychiatric condition resulting from one or more traumatic events, characterized by behavioural and emotional disturbances. Alexithymia, the difficulty in identifying and describing internal emotions, is a significant comorbidity that can exacerbate PTSD symptoms but is often understated. This study aimed to estimate the prevalence of alexithymia in PTSD patients and explore associated factors and potential moderators. METHODS:We conducted a systematic review of the literature, querying three databases for studies on alexithymia in adults with PTSD. Meta-analyses were performed to assess the prevalence of alexithymia and explore its moderators. RESULTS:Thirty-six studies met the inclusion criteria. The pooled prevalence of alexithymia in PTSD patients was 53% (95% CI: 42-65%). The mean TAS score indicated a possible threshold for alexithymia (56.12, 95% CI: 50.77-61.48), with a significant difference in alexithymia scores between PTSD patients and trauma-exposed controls (SMD: 0.78, 95% CI: 0.22-1.34). PTSD severity was positively correlated with alexithymia, and alexithymia was significantly associated with dissociative symptoms. CONCLUSIONS:Alexithymia is a frequent and impactful comorbidity in PTSD, complicating its clinical picture and therapeutic management. The introspective difficulties associated with alexithymia hinder the effectiveness of traditional therapies, and its influence on body-related symptoms suggests that integrating Mind-Body approaches may improve treatment outcomes. Given the significant overlap between alexithymia, dissociation, and trauma exposure, a more tailored, nuanced treatment is needed to enhance emotional regulation and self-awareness in PTSD patients.